Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY-Reference-Cited by-同舟云学术

Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY

Published:2018-07-31 Issue:1 Volume:13 Page:
ISSN:1750-1172
Container-title:Orphanet Journal of Rare Diseases
language:en
Short-container-title:Orphanet J Rare Dis

Author:

Mauhin Wladimir^ORCID,Lidove Olivier,Amelin Damien,Lamari Foudil,Caillaud Catherine,Mingozzi Federico,Dzangué-Tchoupou Gaëlle,Arouche-Delaperche Louiza,Douillard Claire,Dussol Bertrand,Leguy-Seguin Vanessa,D’Halluin Pauline,Noel Esther,Zenone Thierry,Matignon Marie,Maillot François,Ly Kim-Heang,Besson Gérard,Willems Marjolaine,Labombarda Fabien,Masseau Agathe,Lavigne Christian,Froissart Roseline,Lacombe Didier,Ziza Jean Marc,Hachulla Eric,Benveniste Olivier

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Genetics (clinical),General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s13023-018-0877-4.pdf

Reference25 articles.

1. Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, Packman S, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant. 2009;24:2102–11.

2. Mehta A, Hughes DA. Fabry Disease. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJ, et al., editors. GeneReviews(®) [Internet]. Seattle: University of Washington, Seattle; 1993. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1292/ . [cited 7 Jan 2016].

3. Echevarria L, Benistan K, Toussaint A, Dubourg O, Hagege AA, Eladari D, et al. X-chromosome inactivation in female patients with Fabry disease. Clin Genet. 2016;89:44–54.

4. Pan X, Ouyang Y, Wang Z, Ren H, Shen P, Wang W, et al. Genotype: a crucial but not unique factor affecting the clinical phenotypes in Fabry disease. PLoS One. 2016;11:e0161330.

5. Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant. 2006;21:345–54.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarkers in anderson-Fabry disease: what should we use in the clinical practice?;Rare Disease and Orphan Drugs Journal;2024-04-25

2. Mass cytometry reveals atypical immune profile notably impaired maturation of memory CD4 T with Gb3‐related CD27 expression in CD4 T cells in Fabry disease;Journal of Inherited Metabolic Disease;2024-04-16

3. Anderson-Fabry disease cardiomyopathy: an update on epidemiology, diagnostic approach, management and monitoring strategies;Frontiers in Cardiovascular Medicine;2023-06-02

4. An expert consensus on the recommendations for the use of biomarkers in Fabry disease;Molecular Genetics and Metabolism;2023-06

5. Treatment of Fabry Disease: Established and Emerging Therapies;Pharmaceuticals;2023-02-20